CompanyGraph
Mesoblast Limited
MSB · ASX · Australia
Price data from its MSB listing on CXA
mesoblast.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.2B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.23: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.06BAUD2.20B · vs all stocks (USD)
Revenue (TTM)
92.44MAUD66.37M · vs all stocks (USD)
Profit Margin
-144.33%vs Biotechnology peers
Beta
0.8110xvs all stocks
52-Week Change
-3.67%vs all stocks
Market Capitalization
3.06BAUD2.20B · vs all stocks (USD)
Enterprise Value
4.58BAUD3.29B · vs all stocks (USD)
Forward P/E
51.35xvs Biotechnology peers
Price to Sales (TTM)
49.79xvs Biotechnology peers
Price to Book (MRQ)
3.97xvs Biotechnology peers
Enterprise to Revenue
49.54xvs Biotechnology peers
Enterprise to EBITDA
-50.35xvs Biotechnology peers
Profit Margin
-144.33%vs Biotechnology peers
Operating Margin
-55.16%vs Biotechnology peers
Return on Assets (TTM)
-6.16%vs Biotechnology peers
Return on Equity (TTM)
-18.22%vs Biotechnology peers
Revenue (TTM)
92.44MAUD66.37M · vs all stocks (USD)
Revenue per Share (TTM)
0.0510AUDUpdated Aug 22, 2026Quarterly Revenue Growth
1526.80%vs Biotechnology peers
Gross Profit (TTM)
-32.85MAUD-23.58M · vs all stocks (USD)
EBITDA (TTM)
-90.96MAUD-65.31M · vs all stocks (USD)
Net Income (TTM)
-133.41MAUD-95.79M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-3.82%vs Biotechnology peers
Operating Cash Flow (TTM)
-84.32MAUD-60.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-98.17MAUD-70.48M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00AUDUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
17.20MUSDFY2025 · Jun 30, 2025Cost of Goods Sold
5.13MUSDFY2025 · Jun 30, 2025Gross Profit
12.07MUSDFY2025 · Jun 30, 2025Operating Income
-62.44MUSDvs all stocks (USD)
Pre-tax Income
-101.81MUSDFY2025 · Jun 30, 2025Income Tax Expense
330.00KUSDFY2025 · Jun 30, 2025Net Income
-102.14MUSDFY2025 · Jun 30, 2025EBIT
-80.06MUSDFY2025 · Jun 30, 2025EBITDA (Income Statement)
-59.69MUSDFY2025 · Jun 30, 2025Research & Development
34.81MUSDFY2025 · Jun 30, 2025Selling, General & Administrative
39.31MUSDFY2025 · Jun 30, 2025Other Operating Expenses
-85.00KUSDFY2025 · Jun 30, 2025Non-operating Interest Income
3.55MUSDFY2025 · Jun 30, 2025Non-operating Interest Expense
21.75MUSDFY2025 · Jun 30, 2025EPS (Basic)
-0.0846USDFY2025 · Jun 30, 2025EPS (Diluted)
-0.0846USDFY2025 · Jun 30, 2025Basic Shares Outstanding
1.21BSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
1.21BSharesFY2025 · Jun 30, 2025Net Income from Continuing Operations
-102.14MUSDFY2025 · Jun 30, 2025Operating Cash Flow
-63.70MUSDFY2025 · Jun 30, 2025Free Cash Flow
-64.38MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
161.55MUSDFY2025 · Jun 30, 2025Starting Profit (CF Statement)
-102.14MUSDFY2025 · Jun 30, 2025Depreciation & Amortization
6.40MUSDFY2025 · Jun 30, 2025Deferred Taxes (CF)
330.00KUSDFY2025 · Jun 30, 2025Stock-based Compensation
22.09MUSDFY2025 · Jun 30, 2025Other Non-cash Items
21.43MUSDFY2025 · Jun 30, 2025Change in Accounts Receivable (CF)
6.29MUSDFY2025 · Jun 30, 2025Change in Other Assets/Liabilities
-18.09MUSDFY2025 · Jun 30, 2025Capital Expenditures
-680.00KUSDFY2025 · Jun 30, 2025Net Intangibles (CF)
-50.00KUSDFY2025 · Jun 30, 2025Sale of Investments
241.00KUSDFY2025 · Jun 30, 2025Other Investing Activity
609.00KUSDFY2025 · Jun 30, 2025Net Investing Cash Flow
170.00KUSDFY2025 · Jun 30, 2025Long-term Debt Payments
-9.77MUSDFY2025 · Jun 30, 2025Common Dividends Paid
0.00USDFY2025 · Jun 30, 2025Other Financing Charges
-5.66MUSDFY2025 · Jun 30, 2025Net Financing Cash Flow
145.78MUSDFY2025 · Jun 30, 2025Shares Outstanding
1.30BSharesUpdated Aug 22, 2026Float Shares
836.76MSharesUpdated Aug 22, 2026% Held by Insiders
36.28%vs all stocks
% Held by Institutions
16.97%vs all stocks
Total Cash (MRQ)
183.75MAUD131.93M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1010AUDUpdated Aug 22, 2026Total Debt (MRQ)
191.06MAUD137.18M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2352xvs Biotechnology peers
Current Ratio (MRQ)
1.58xvs Biotechnology peers
Book Value per Share (MRQ)
0.6322AUDUpdated Aug 22, 2026Total Assets
784.68MUSDvs all stocks (USD)
Total Current Assets
204.35MUSDFY2025 · Jun 30, 2025Total Liabilities
187.24MUSDFY2025 · Jun 30, 2025Total Non-current Assets
580.33MUSDFY2025 · Jun 30, 2025Total Non-current Liabilities
84.61MUSDFY2025 · Jun 30, 2025Total Current Liabilities
102.63MUSDFY2025 · Jun 30, 2025Cash
161.16MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents
161.16MUSDFY2025 · Jun 30, 2025Accounts Receivable
13.91MUSDFY2025 · Jun 30, 2025Inventory
22.25MUSDFY2025 · Jun 30, 2025Accounts Payable
19.08MUSDFY2025 · Jun 30, 2025Short-term Debt
56.84MUSDFY2025 · Jun 30, 2025Other Current Liabilities
16.73MUSDFY2025 · Jun 30, 2025Long-term Debt
71.32MUSDFY2025 · Jun 30, 2025Other Non-current Liabilities
10.78MUSDFY2025 · Jun 30, 2025Common Stock (Book)
1.51BUSDFY2025 · Jun 30, 2025Retained Earnings
-1.01BUSDFY2025 · Jun 30, 2025Total Shareholders' Equity
597.44MUSDvs all stocks (USD)
52-Week Low
1.88AUDUpdated Aug 22, 202652-Week High
3.31AUDUpdated Aug 22, 202652-Week Change
-3.67%vs all stocks
Beta
0.8110xvs all stocks
50-Day MA
2.20AUDUpdated Aug 22, 2026200-Day MA
2.32AUDUpdated Aug 22, 2026Avg 10-Day Volume
2.56MSharesUpdated Aug 22, 2026Avg 30-Day Volume
3.28MSharesUpdated Aug 22, 2026Diluted EPS (TTM)
-0.1200AUDUpdated Aug 22, 2026Other Income / Expense
-20.37MUSDFY2025 · Jun 30, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.23: safe zoneNotable
Altman Z-Score: 5.23
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.2B, above the global median of $1.15BNotable
Market cap (USD): 2,197,674,256.29Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
MeHow Innovative Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wedge Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fujian Cosunter Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sionna Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Iovance Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zai Lab Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Neogen Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Granules India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
XTL Biopharmaceuticals Ltd.
3 interpretationsGoodwill-Heavy EquityIntangible ConcentrationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Olaplex Holdings, Inc.
2 interpretationsGoodwill-Heavy EquityIntangible Concentration
Tribal Group plc
2 interpretationsGoodwill-Heavy EquityIntangible Concentration